Table 1.
Certain marine natural compounds are potential anticancer drugs
| Compound | Biological source | Chemical nature | Action mechanism | Company | Status |
| Bryostatin-1 (7) | Bryozoan | Poliketide | Inhibitor of protein kinase | GPC Biotech | Phase 2 clinical trials |
| Dolastatin-10 (8) | Mollusc | Peptide | Inhibitor of microtubeles formation | NCI-Knoll | Phase 2 clinical trials of its derivative TZT-1027 |
| HTI286 (9) | Sponge | Tripeptide | Inhibitor of microtubeles formation | Novartis | Continuation of clinical trials |
| Discodermalide (10) | Sponge | Poliketide | Inhibitor of microtubeles formation | Novartis | Phase 2 clinical trials |
| Cryptophycin (11) | Cyanobacterium | Cyclic depsipeptide | Inhibitor of microtubeles formation | Eli Lilly | Taken out from phase 2 clinical trials |
| Aplidin (12) | Ascidian | Cyclic depsipeptide | Causes oxidative stress in cells | PharmaMar | Phase 2 clinical trials |
| Eribulin mesylate (13) | Sponge | Polyether derivative | Inhibitor of microtubeles formation | Esai Company | Phase 3 clinical trials |
| Squalamine (14) | Shark | Steroid | Inhibitor of angiogenesis | Genaera | Taken out from phase 2 clinical trials |
| Kohalalide F (15) | Mollusc | Cyclic depsipeptide | Active on lysosomal level | PharmaMar | Phase 2 clinical trials |
| Salinosporamide A (16) | Marine bacterium | Lactam-lactone derivative | Proteosome inhibitor | Nereus | Phase 2 clinical trials |